PU.1-IN-1
Based on 1 publication(s) in Google Scholar
PU.1-IN-1 is a potent PU.1 inhibitor with an IC50 of 2 nM. PU.1-IN-1 reduces rMANF-induced miR-223 expression. PU.1-IN-1 exhibits anti-inflammatory properties.
For research use only. We do not sell to patients.
- Purity : 99.72%
- CAS No.: 873588-27-3
- Formula: C18H22N2O2S
- Molecular Weight:330.44
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) PU.1-IN-1
More
Biological Activity
Description
IC50 & Target
IC50: 2 nM (PU.1)[1]
In Vitro
PU.1-IN-1 (Compound A11) inhibits PU.1 with an IC50 of 2 nM[1].
PU.1-IN-1 (PU.1 inhibitor; 1 h) reduces the miR-223 expression induced by rMANF in bone marrow neutrophils[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
CAS No. 873588-27-3
-
Appearance Solid
-
Molecular Weight 330.44
-
Formula C18H22N2O2S
-
Color White to off-white
-
SMILES
O=S(C1=CC=C(C2CCCCC2)C=C1)(NCC3=CC=NC=C3)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
J Gastroenterol
Myeloid-derived MANF ameliorates ethanol-induced liver injury by enhancing microRNA-223 expression. [Abstract]2025 Jul;60(7):877-890. PMID: 40111540
Solvent & Solubility
In Vitro:
DMSO : 100 mg/mL (302.63 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 1% DMSO 99% Saline
Solubility: 0.25 mg/mL (0.76 mM); Suspended solution; Need ultrasonic
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocols
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
Purity & Documentation
-
Data Sheet (272 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.0263 mL | 15.1313 mL | 30.2627 mL | 75.6567 mL |
| 5 mM | 0.6053 mL | 3.0263 mL | 6.0525 mL | 15.1313 mL | |
| 10 mM | 0.3026 mL | 1.5131 mL | 3.0263 mL | 7.5657 mL | |
| 15 mM | 0.2018 mL | 1.0088 mL | 2.0175 mL | 5.0438 mL | |
| 20 mM | 0.1513 mL | 0.7566 mL | 1.5131 mL | 3.7828 mL | |
| 25 mM | 0.1211 mL | 0.6053 mL | 1.2105 mL | 3.0263 mL | |
| 30 mM | 0.1009 mL | 0.5044 mL | 1.0088 mL | 2.5219 mL | |
| 40 mM | 0.0757 mL | 0.3783 mL | 0.7566 mL | 1.8914 mL | |
| 50 mM | 0.0605 mL | 0.3026 mL | 0.6053 mL | 1.5131 mL | |
| 60 mM | 0.0504 mL | 0.2522 mL | 0.5044 mL | 1.2609 mL | |
| 80 mM | 0.0378 mL | 0.1891 mL | 0.3783 mL | 0.9457 mL | |
| 100 mM | 0.0303 mL | 0.1513 mL | 0.3026 mL | 0.7566 mL |
PU.1-IN-1 Related Classifications
HY-W176171 Related Classifications
Powered by Bioz